𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Continuous epoprostenol therapy and septal defect closure in a patient with severe pulmonary hypertension

✍ Scribed by Aki Hirabayashi; Katsumasa Miyaji; Teiji Akagi


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
174 KB
Volume
73
Category
Article
ISSN
1522-1946

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Improvement in pulmonary hemodynamics du
✍ Michael J. Krowka; Robert P. Frantz; Michael D. McGoon; Cathy Severson; David J. πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 125 KB

Pulmonary hypertension associated with increased pulmonary vascular resistance (PVR) and occurring in the setting of portal hypertension is referred to as ''portopulmonary hypertension.'' Intravenous epoprostenol (prostacyclin) is a potent pulmonary and systemic vasodilator with antithrombotic prope

Stent implantation in right-sided patent
✍ Sanjay Tyagi; Girish Dwivedi; Mohit Dayal Gupta; Upkar A. Kaul πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 107 KB πŸ‘ 2 views

## Abstract Patients with unrepaired pulmonary atresia and ventricular septal defect may develop stenosis of collaterals or shunts to the pulmonary arteries leading to hypoperfusion of lungs and systemic hypoxemia. A 25‐year‐old female with pulmonary atresia and ventricular septal defect presented

Long-term iloprost infusion therapy for
✍ Jose De La Mata; Miguel A. Gomez-Sanchez; Mercedes Aranzana; Juan J. Gomez-Reino πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 613 KB

Objective. To determine the effects of short-term, maximum-tolerated-dose and long-term, optimum-dose iloprost treatment of severe pulmonary hypertension associated with systemic sclerosis (SSc) and the primary antiphospholipid syndrome (APS). Methods. Three patients with SSc and 2 with APS who had